Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium

NCT01551030 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

19

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Transitional Cell Carcinoma of the Urothelium

Interventions

DRUG: Buparlisib

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]